Loading…

Real-world data from Europe and Africa suggest that accuracy of systems for self-monitoring of blood glucose is frequently impaired by low hematocrit

•Hematocrit outside common glucose meter performance limits is not uncommon.•3% of outpatients in Europe have hematocrit outside commonly specified ranges.•This is especially the case for older subpopulations with higher diabetes prevalence.•In South Africa, low hematocrit is even more common, and a...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes research and clinical practice 2021-07, Vol.177, p.108860-108860, Article 108860
Main Authors: Hinzmann, Rolf, Militz, Daniel, Zima, Tomáš, Špaček, Martin, Storm, Huib, Chapanduka, Zivanai, Hauss, Oliver
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Hematocrit outside common glucose meter performance limits is not uncommon.•3% of outpatients in Europe have hematocrit outside commonly specified ranges.•This is especially the case for older subpopulations with higher diabetes prevalence.•In South Africa, low hematocrit is even more common, and across all age strata.•Patients diagnosed with diabetes should be carefully matched with SMBG instruments. Certain systems for self-monitoring of blood glucose (SMBG) demonstrate inaccuracy at low and high hematocrit (HCT). Manufacturers define HCT ranges for accurate performance. Our objective was to assess the frequency of HCT values that can lead to clinically relevant errors. In this cross-sectional study, we collected real-world data representing over 360,000 outpatients from the Netherlands (NL), the Czech Republic (CZ), and South Africa (ZA). These were subsequently stratified by sex and age and compared to commonly specified HCT range limits, reference intervals, and data from 1780 healthy Czech subjects. HCT values were comparably distributed in NL and CZ. Outpatients had a higher dispersion of values than healthy subjects. Low HCT values in Europe were common in age groups with a high prevalence of diabetes. All ZA age groups showed a higher prevalence of low HCT than in Europe. Real-world data indicate that SMBG systems specified to perform only within the frequently used 30–55% HCT range would leave 3% of outpatients in Europe and 18% in South Africa at risk of false SMBG results, with individual age strata being substantially higher. This could affect their diabetes management. Adequate SMBG systems should thus be chosen.
ISSN:0168-8227
1872-8227
DOI:10.1016/j.diabres.2021.108860